Contrast-enhanced ultrasound with microbubbles has shown promise in detection of prostate cancer (PCa), but sensitivity and specificity of detection remain challenging. Targeted nanoscale contrast agents with improved capability to accumulate in tumors may result in prolonged signal enhancement and improved detection of PCa with ultrasound. Here we report on a new nanobubble contrast agent that specifically targets prostate specific membrane antigen (PSMA) overexpressed in most prostate tumors. The PSMA-targeted bubbles (PSMA-NB) were utilized to simultaneously image dual flank PCa tumors (PSMA-positive PC3pip and PSMA-negative PC3flu) to examine whether the biomarker can be successfully detected and imaged using this probe in a mouse model. Results demonstrate that active targeting of NBs to PSMA rapidly and selectively enhances tumor accumulation and is critical for tumor retention of the contrast agent. Importantly, these processes could be visualized and quantified, in real time, with standard clinical ultrasound. Such demonstration of the immense yet underutilized potential of ultrasound in the area of molecular imaging can open the door to future opportunities for improving sensitivity and specificity of cancer detection using parametric NB-enhanced ultrasound imaging.
the face of other positive clinical risk factors results in almost 50% of patients undergoing second, if not third and fourth, prostate biopsies leading to increased costs and risk associated with unnecessary procedures. If the already-on board US technology can be used to more reliably identify the location of prostate cancer within the prostate gland, these outcomes stand to be significantly improved.
Contrast-enhanced ultrasound has been investigated as one option for improved PCa detection [6] [7] . In order to increase the PCa detection rate while limiting the number of biopsy procedures, significant effort has been focused on formulation of lipid and/or protein-stabilized gas filled contrast agents to improve the US imaging capability of cancer within the prostate [8] [9] [10] .
Most of these efforts have utilized micron-sized contrast agents or microbubbles (MBs) 9, [11] [12] , which are already clinically utilized for other applications, but these have lacked specificity and sensitivity over conventional methods. One option to improve these parameters is molecular targeting of microbubbles to vascular biomarkers. One example of this approach currently in clinical trials is BR55 (Bracco, Geneva, Switzerland) [13] [14] [15] , which is targeted to vascular endothelial growth factor receptor 2 (VEGFR2). BR55 was examined recently in a phase 0 study for its ability to detect PCa 16 . The reported detection of malignant lesions with BR55 was 68%. {Smeenge, 2017
#42}. Two factors may confound the use of MBs for this application. The first is their large footprint, which confines MBs to the blood stream, and makes consistent targeting and retention at vascular markers. It also makes most biomarkers for PCa and other cancer inaccessible, since most lie beyond the vasculature in the tumor parenchyma. Second, MBs have a short lifespan (typically < 10 min) in the circulation, making their utility limited during targeting and during the entire biopsy procedure.
These unmet needs have led to increased interest in nano-sized US contrast agents that can penetrate the tumor parenchyma, bind to cancers, and exhibit nonlinear contrast behavior similar to MBs [18] [19] [20] [21] [22] [23] . Our group has recently developed an ultrastable nanobubble contrast agent (NB) that contains perfluoropropane inside a propylene glycol and glycerol-enhanced lipid shell, which demonstrated unique physicochemical properties and an extended life span in vivo 24 . These NBs should have the ability to pass though hyper-permeable vasculature in tumors [25] [26] [27] . Furthermore, active targeting to a biomarker overexpressed on prostate cancer should enhance the retention of administered NBs at the tumor site, thus facilitating enhanced molecular contrast imaging in the tumor. A well-known biomarker for PCa is the prostate specific membrane antigen (PSMA) [28] [29] [30] .
PSMA is a type II integral membrane protein that is expressed at lower levels in the healthy prostate and other organs such as the kidney, liver, and brain, but significantly at higher levels in PCa [31] [32] . The level of PSMA has a positive correlation with the pathological phase of the tumor stage [33] [34] [35] and is also considered to be the most important protein target in diagnostic specific immunolocalization imaging and immune-directed therapy 31, 33, 36 . Many ligands specific to PSMA are available, including monoclonal and engineered antibodies, small sized molecules, nanobodies, and aptamers [9] [10] In the current study, we demonstrate the use of standard nonlinear contrast-enhanced US for real-time molecular imaging of PCa by targeting stable NBs to PSMA via the PSMA-1ligand, which has been previously validated as a robust marker for PCa [37] [38] (Fig. 1a ). Our data demonstrate significant, sustained differences between the kinetics of PSMA-NB, NB and MB in PCa models. Specifically, the PSMA-NBs were rapidly taken up by the PSMA-expressing tumors and were selectively retained within the tumor parenchyma, significantly extending duration the signal available for US visualization compared to untargeted NBs and the commercially available MB, Lumason®. No differences were seen in the PSMA-negative tumors or kidneys between NBs and PSMA-NBs, suggesting that the observed retention is due to specific molecular targeting to PSMA in the tumor itself. Notably, since clinical US was consistently capable of distinguishing these kinetic differences in small tumors, the work lays the foundation for future work utilizing the technique in real-time US biopsy guidance. 
Results

Validation and Characterization of PSMA Targeted NB
The conjugation of PSMA-1 to lipids was confirmed by the HPLC and the MALDI-TOF-MS techniques (Supplementary Fig. 1.a, b) . HPLC data showed that the PSMA-1 peak disappeared after conjugating PSMA-1 with DSPE lipid. MALDI-TOF-MS results further confirmed the conjugation of PSMA-1 to the DSPE lipid. The preparation and characterization of base ultrastable NBs has been reported elsewhere 24 . Briefly, the NB hydrodynamic diameter and concentration were characterized using resonant mass measurement (RMM) capable of detecting both buoyant (bubbles) and non-buoyant particles (liposomes, micelles, lipid debris, etc.). The RMM technology operates by measuring the change in the frequency of oscillation of particles that flow through an oscillating cantilever 24, [39] [40] [41] . The size and the concentration of PSMA-NB were 277±11 nm and 3.9E11 ±2.82E10 NBs/ml respectively. The mean size and the concentration did not change significantly after DSPE-PSMA was incorporated into the NBs (Fig.1b and Fig.   1c ). Apart from gas filled bubbles, we also detected non-buoyant particles in both bubble solutions, which are invisible under US, but may contribute to the bubble overall stability 42 (Fig. 1b) . The slightly negative values of zeta potential crucial to the stability of both targeted and untargeted NB (Fig. 1c) were also confirmed using DLS measurement.
In vitro cellular uptake studies
To After the optimal ligand density was established, we then compared the cellular uptake of Rhodamine-PSMA-NB in PSMA-positive (PC3pip) cells and PSMA-negative (PC3flu) cells as shown in Fig. 2a . When cells were exposed to Rhodamine-NB, similar fluorescence intensity was observed in PC3pip and PC3flu cells. When PC3flu cells were exposed to Rhodamine-PSMA-NB, the fluorescent intensity was not significantly different compared to cells exposed to Rhodamine-NB ( Fig. 2b) . In contrast, the signal increased dramatically in PC3pip cells (~10 fold increased), which express PSMA, when treated with Rhodamine-PSMA-NB, indicating that PSMA-NBs selectively bind to PSMA-expressing cells. 
In vivo ultrasound imaging
In vivo experiments examining the kinetics of targeted PSMA-NB and NB were performed using clinical nonlinear contrast enhanced ultrasound and the average results from 7 mice are reported (Fig. 3.) . Five quantitative parameters related to perfusion and bubble dispersion were extracted from the acquired time-intensity-curves (TIC). These include peak intensity, time to peak, the duration of contrast enhancement, and area under the curve. The parameters were compared between PSMA-NB and NB in the PSMA-positive PC3pip and PSMA-negative PC3flu tumors. Additional comparison was made with the commercially available microbubble, Lumason®. (Fig. 3a) . A total of 200 µl of undiluted NB (~8 x 10 10 PSMA-NB or NB) were injected through the tail vein, and continuous contrast mode US was performed to visualize the bubble dynamic in the tumors and the kidney. Rapid enhancement of the contrast was observed first in the kidneys followed by both tumors approximately 30 sec to 2 min post-injection. The time to peak for PSMA-NB in the PC3pip tumor was slightly longer but it is not significantly different compared to that of PSMA-NB in PC3flu, (Supplementary Fig. 3a ; 3.97 ± 1.20 min compared to 2.75 ± 1.31 min, P = 0.09).
Furthermore, there was no significant difference between the time to peak for NB in either PC3pip
or PC3flu tumor (P = 0.21). The average peak intensity was measured to be 15.64 ± 0.42 dB for PSMA-NB and NB in the PC3pip and PC3flu tumors and it is not significantly different in each case (Supplementary Fig. 3b) . The NB accumulation was compared and validated using clinically available MB-Lumason®. The peak intensities obtained for PSMA-NB (15.96 ± 1.83 dB) and NB (15.60 ± 2.53 dB) were significantly different from the one observed with the Lumason® (7.38 ± 0.33 dB, p < 0.001). Also, the duration of signal enhancement with Lumason® was limited to < 5 min indicating low stability and low circulation time of Lumason® MB in the blood stream. Table 1 shows the quantitative parameters obtained from the time intensity curves, including peak enhancement, time to peak, area under the curve (AUC), and 25% of the maximum peak. Importantly, the AUC was calculated for wash in (WiAUC) and wash out (WoAUC) phases separately, since the main differences in bubble dynamics were expected during the washout phase.
The total AUC is shown in Supplementary Fig. 3c . The WiAUC for all cases were consistent, however, the WoAUC of PSMA-NB in PC3pip tumor showed a significant, 2-fold increase, compared to all other groups (Supplementary Fig. 3d ; p < 0.001). Since the TIC are similar in all cases at the early time points, but deviate at the later time points, the half peak maximum or the half time of peak intensity (t50%) was also similar between groups (data not shown). However, the time to reach 25% of the maximum peak intensity (t75%) for PSMA-NB in PC3pip tumor was 2-fold longer than all other groups (p < 0.01) ( Table 1) . These results indicated prolonged retention of targeted NB in PSMA-expressing tumors.
To further clarify the effect that active nanobubble targeting on tumor accumulation, the signal from PSMA-NB was normalized to the signal from NB in both PC3pip and PC3flu tumors at selected time points. This was enabled by the fact that each mouse in the cohort received a randomized injection of both targeted and untargeted NBs. Thus, we can compare the effect of targeting, and of target expression in tissue, in addition to any unrelated confounding effects that may result from surface functionalization of the bubbles. No significant differences were noted between PSMA-NB and NB groups for the time to peak, peak max, WiAUC in kidneys. Although the AUC in kidney with PSMA-NB injection was higher compared to the NB group, there is no significant difference between the two types of NBs (Supplementary Fig. 3c ). Moreover, in the kidneys there was no significant difference in t50 % or t75% values between PSMA-NB and NB (data not shown). 
Histology
To further validate that PSMA-targeted NB can extravasate into the tumor matrix, the bubbles were tagged with a fluorescent dye; Cy5.5, and injected via tail vein. Twenty-five min post-injection, the anesthetized animal was euthanized using cardiac perfusion with saline to remove all blood and concurrently all circulating bubbles. The tumors and kidneys were harvested for histological analysis. In animals harboring the PC3pip tumors, the Cy5.5-PSMA-NB signal can be seen deep in the tissue, distally from the microvasculature, providing strong evidence that the targeted NBs extravasate from the vasculature and enter the tumor interstitial space (Fig. 5a) .
The Cy5.5-PSMA-NB signal in PC3pip tumor was significantly higher (5.4 fold) compared to retained signal in tumors that did not express PSMA, PC3flu tumor (P < 0.001) (Fig.5b) . Likewise, non-targeted Cy5.5-NB had low accumulation in both PC3pip and PC3flu tumors, which was comparable to targeted NB levels in the PC3flu tumors after perfusion. We noted no significant histological differences of vasculature between both types of tumors when sections were stained with anti-CD-31 (Fig 5b) . Quantification of the Cy5.5 labeled bubbles revealed that the targeted bubbles showed 5-fold more accumulation and localization with the CD31 stained vasculature in the PC3pip compared to PC3flu tumors (Fig 5d) . The overexpression of the PSMA in the PC3pip cells was confirmed by immunohistochemistry results (Fig. 5 c, e; 63.66± 1.51 vs 1.83± 0.15). 
Discussion
Currently, PCa biopsies often provide false negative results. Consequently, there is a critical need for improved tools for PCa detection that can be used to better inform biopsy procedures. A wide range of imaging approaches is being examined to fill this unmet need, with MRI-guided biopsies and MRI preplanning showing the most promise [44] [45] [46] [47] [48] [49] . Multiparametric MRI (mpMRI) and MRI-guided in gantry biopsies have been used in the clinic, and some sites have
shown that the rate of PCa detection with these procedures is improved compared to transrectal US-guided biopsies [45] [46] [47] [48] [49] . However, MRI-based exams and procedures still present a number of challenges for broad adoption: they are not widely available, they are not portable and have a confined working space, and they require additional expertise outside of urology (e.g. radiology).
The procedures can also be quite expensive and add significant time and cost to the diagnostic workflow. Finally, the negative predictive value (the ability to confidently state that a patient is malignancy-free), while hugely beneficial, has not been shown to be effective at this point with MRI [50] [51] .
A large body of work has instead focused on use of contrast enhanced US that are capable of molecular level imaging for this application. However, due to the rapid dissipation of encapsulated gas that causes a rapid signal decay, MB have a short in vivo half-life, which is not subtle enough to delineate pathological tissues from surrounding normal tissues for US-guided biopsies. Currently, the most promising MB tool is BR55, which targets VEGFR2 14-15, 52 , as discussed above, also has comparatively low specificity and sensitivity. While MBs are useful for visualizing vascular targets, they are restricted to the blood pool. In contrast, nano-sized particles may be able to penetrate leaky tumor vasculature to reach tissue targets located outside of vessels.
In order to achieve sufficient dosage to gain a predominant signal at the target, the nanoparticles should outflow from the physical and biological barriers in the body, such as renal clearance, etc [53] [54] [55] . Formulation of NBs with a robust and resilient shell has prolonged their circulating time in vivo 24 . In the current study, in order to achieve specific US molecular imaging, the NBs were targeted to PSMA, which is expressed in high level in both androgen-dependent PCa and androgen-independent PCa, and a common target for PCa US imaging [9] [10] . Consequently, PSMA-Bubble diameter and concentration obtained using resonant mass measurement indicated that both NB and the PSMA-NB are in nanoscale (< 300 nm) range and have a concentration several orders of magnitude higher than commercial MB agents. The small size and high shell deformability facilitated by inclusion of the edge activator, propylene glycol 56 may enable NBs to pass through the neovasculature [57] [58] . The in vitro cell uptake studies provided the optimum concentration of PSMA-1 that can be incorporated into the NBs to achieve peak uptake. The optimum ligand density obtained (35 x 10 3 ligands per NB) concurred with the reported values 43 .
Cell uptake studies also demonstrated selectivity of binding of PSMA-NBs to the PSMA-positive PC3pip tumor cells.
In the in vivo acoustic evaluation, the nondestructive low mechanical index (MI = 0.1) was used to construct TIC and the parametric dynamic CEUS imaging was used to derive the contrast kinetics. Most importantly, this data demonstrates selective uptake of PSMA-NB in PSMApositive PC3pip tumors compared to the PSMA-negative PC3flu tumors. In comparing the contribution of active targeting to this behavior it was crucial to also examine untargeted NB in the same tumors, thus mice received a randomized injection of these bubbles in the same exam, either before or after PSMA-NB administration. We observed that the time to peak and maximum peak enhancement were similar in both groups, signifying the similar dynamic of PSMA-NB and NB in the blood stream and also comparable morphology and vasculature in both PC3pip and PC3flu tumors. In stark contrast, the washout was slower with PSMA-NB in the PC3pip tumor compared to all other groups, as shown by persistent enhancement over 30 min, 2-fold higher WoAUC and t75% . Preferential accumulation of PSMA-NB in the PSMA expressing tumors was noticeable as early as 10 min after injection and increased over time. This is a considerable improvement over the relatively small and transient differences noted in prior studies of PSMAtargeted contrast agents [9] [10] . Lumason® MB exhibited significant rapid enhancement in the kidney and relatively minor enhancement in tumors, and were cleared from the circulation rapidly without any significant binding. The high tumor to kidney signal ratio with PSMA-NB in PC3pip tumor also supports the conclusion that targeted NBs accumulate in PSMA-expressing tumors. However, to fully elucidate the fate of NB in the tumor tissue, a 3D imaging modality will be more informative compared to 2D imaging; these studies are currently ongoing.
Histological findings confirm the PSMA targeted NB can specifically recognize the tumors with PSMA expression. The percentage of PSMA-NB in PC3pip tumor is approximately 6-fold higher than that in PC3flu tumor. There bubbles were previously shown to also be intact and capable of generating acoustic activity, even following tumor perfusion 59 . The data also revealed that PSMA appears to be present in the tumor vasculature, which is a well-documented phenomenon for many tumors including some prostate cancers 60 . Concurrent with this we observed signal from PSMA-NB in the neovasculature in some PC3pip tumors even after the whole body perfusion of the animal (data not shown). Moreover, the histology data showed an increase of PSMA-NB accumulation in kidneys. While absolute levels were small, the PSMA-NB signal in the kidney was on average 6-fold higher compared to the NB signal ( Supplementary   Fig. 4a, b) . Notably, we observed positive signal from PSMA in kidney, yet approximately 30% lower compared to the PC3pip tumor (Supplementary Fig. 4c ). Despite this unexpected expression, the kidney normalized data in Fig 4b above shows increasing enhancement in the PC3pip tumors over 30 min, indicating that the affinity, biding and retention of PSMA-NBs in tumors is considerable.
Conclusion
The prolonged persistence of US signal of PSMA-NB in PCa provides exciting future opportunities to facilitate improved PCa detection with multiparametric contrast-enhanced ultrasound. The same principles can also make real-time PCa biopsies with US guidance a reality in the future. Additional studies are ongoing to also examine in detail extravasation of nanobubbles in tumors and quantify their acoustic activity following extravasation. Furthermore, in depth studies will elucidate the capability of PSMA-NB in delineating PCa using orthotropic PCa in mouse and larger animal models with the eventual goal of clinical translation into a rapid real-time biopsy guidance strategy.
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